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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not is
metoclopramide effective in treating symptoms in diabetic gastroparesis?
Study Design: Systematic review of 1 controlled randomized double blinded study, 1controlled
randomized open label study, and 1 controlled open label case analysis published in peer
reviewed journals between 2012-2014, all in English language.
Data Sources: 1 randomized double blinded study, 1 randomized open label study, and 1 case
analysis comparing symptom reduction of gastroparesis after the intervention of nasal and oral
metoclopramide compared to placebo controls. These sources were found using PubMed and
OVID.
Outcomes Measured: Patients graded their symptoms on a scale and graded the severity of each
symptom after the use of nasal and oral metoclopramide. The studies gave patients different
scales to measure the severity of each symptom which included a Symptom Assessment
Questionnaire (SAQ), Gastroparesis Cardinal Symptom Index Daily Diary, and a Clinical Patient
Grading Assessment Scale (CPGAS). 5,6,7
Results: Conclusively, the studies did not show a reduction in symptoms after the intervention
for gastroparesis in diabetic patients. Only one study demonstrated symptom reduction to be
statistically significant while the other two studies did not.
Conclusions: The use of metoclopramide did not show an improvement in gastroparesis
symptoms as assessed by patients after the use of the medication from these studies. More RCT
need to be done to prove this scientifically rather than through patient report due to bias or
misunderstanding of scoring and through a trial using same comparison groups for a longer
duration.
Key Words: Gastroparesis, Metoclopramide
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INTRODUCTION
Diabetes is the seventh leading cause of death in the United States and is prevalent in
about 30.3 million Americans as of 2015. 1 Diabetes as the primary medical condition results in
34.6 million health care visits in the past year. 1 The health care cost of a diabetes in 2017 in the
United States was about $327 billion.1 Type 1 Diabetes is caused by a deficiency in insulin due
to autoantibodies that form and attack the pancreatic islet beta cells that develops usually before
the age of 20, resulting in hyperglycemia. Type 2 diabetes is mainly due to insulin resistance,
insulin insufficiency, and elevated hepatic glucose production over time, also resulting in
hyperglycemia, and commonly seen with obesity. 1 The prevalence of diabetes is increasing
drastically with 50 to 65% of patients with diabetes mellitus also having a diagnosis of
gastroparesis.2 Diabetic gastroparesis is more prevalent in type 1 diabetics, but it is also seen in
type 2 diabetics as well.
Gastroparesis is delayed gastric emptying that is seen in both type 1 and type 2 diabetes.
This results in nausea, vomiting, belching, abdominal pain, heart burn, and early satiety. The
exact etiology of diabetic gastroparesis is unknown and there is no ultimate cure other than to
provide some relief of symptoms with changes in diet and using certain medications such as
metoclopramide.3 It is suggested that gastroparesis occurs due to damage to the vagus nerve
which controls the movement of food through the digestive tract. 3
Metoclopramide, a prokinetic, increases muscle contractions in the digestive tract. Other
than gastroparesis, Metoclopramide’s other uses involve the treatment of heartburn caused by
gastroesophageal reflux disease.3,4 Other treatments to manage gastroparesis include controlling
diet which is usually the initial step. Fatty, spicy, and acidic foods, and carbonated drinks should
be avoided.4 This, however, only works for mild cases of gastroparesis. Hydration is key in
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patients who have vomiting symptoms. Nutritional deficiencies can also arise in this specific
group of patients due to vomiting episodes and resistance to eat due to nausea. Due to these side
effects of gastroparesis, replenishing micronutrients is essential. Other treatments for targeting
other symptoms of gastroparesis include erythromycin, prochlorperazine, diphenhydramine, and
ondansetron. Refraining from smoking is also insisted in gastroparesis patients. A
nonconventional method includes acupuncture. 4 Lastly, surgical treatment is reserved for patients
who are unable to tolerate any types of food at all, which includes a jejunostomy tube. 4
Diabetic patients struggle to maintain their quality of life with trying to balance diet,
exercise, frequent doctor and pharmacy visits, insurance difficulties, and treatment adherence.
Diabetes causes an increase in glucose in the body which delays emptying food from the
stomach to the intestines which causes an arousal of symptoms. Gastroparesis adds further stress
to a diabetic patient decreasing their quality of life furthermore. Since so much of the population
if affected by diabetes and its immense list of complications, one being gastroparesis, it is
essential for all healthcare providers to be knowledgeable so that proper guidance and effective
treatment can be recommended for patients. This paper evaluates the effectiveness of
metoclopramide for gastroparesis symptoms in diabetic patients, compared to nasal and oral
forms of metoclopramide, as well as to the placebo control.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not is
Metoclopramide effective in treating symptoms in diabetic gastroparesis?
METHODS
This selective EBM review examined three studied which included 1 randomized double
blinded study, 1 randomized open label study, and 1 open label case analysis comparing
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symptom reduction of gastroparesis after the intervention of nasal and oral metoclopramide
compared to placebo controls.5,6,7 The population included male and female patients older than
18 years of age with a diagnosis of diabetes and gastroparesis. The intervention used in each of
the studies was metoclopramide 14 mg and 20 mg nasal spray, as well as oral metoclopramide 10
mg.5,6,7 Treatment groups received the nasal metoclopramide and the control group received the
oral metoclopramide or placebo. The outcomes measured in each was whether there was a
reduction in symptoms of gastroparesis after the intervention of metoclopramide for patients
experiencing gastroparesis, furthermore if there was a better prognosis when comparing nasal to
oral metoclopramide. All studies were published in the English language and were published
between 2012 through 2014. The studies were found using two keywords “Gastroparesis” and
“Metoclopramide” through PubMed and OVID. Articles were selected based on their relevance
to the clinical question and had patient oriented outcomes (POEMS). Inclusion criteria included
studies that were randomized, controlled, double blind, open label, and case analysis studies that
measured the effectiveness of metoclopramide in gastroparesis patients. It also included patients
taking metoclopramide or patients who had a diagnosis of gastroparesis. Articles written over 10
years ago and patients under the age of 18 were excluded as part of the exclusion criteria.
Statistics reported were p-values, relative benefit increase (RBI), numbers needed to treat (NNT),
and absolute benefit increase (ABI). The demographics and characteristics of the individuals
included in these studies are displayed in Table 1.
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Table 1 – Demographics & Characteristics of included studies

Study

Type

#
Pts

Age
(yrs)

Inclusion Criteria

Exclusion
Criteria

W/D

Interventions

Parkman5
HP, 2012

Open Label
Case
Analysi
s

100

>18
years of
age

Patients 18 years of age
and older receiving or
having received
metoclopramide treatment
as part of their regular
clinical care, and able to
provide informed consent
to participate in the study.

Patients with
a fasting
glucose
>280 mg/dL
did not meet
the standards
to be a
candidate.

0

Metoclopramide

Parkman6
HP, 2015

Double
Blind
RCT

225

18-75
years of
age

18 to 75 years of age with
type 1 or type 2 DM with
a diagnosis of
gastroparesis, and who
had a mean daily GCSI–
DD score between 2-4 for
the 7 days before the
randomization visit (day
0) and were willing to
discontinue treatment for
diabetic gastroparesis.

Subjects
with a mean
GCSI–DD
total score of
less than 2.0
or greater
than 4.0
during the
washout
period were
excluded.

2

Metoclopramide
14 mg Nasal
Spray

Parkman7
H, 2014

OpenLabel
RCT

89

18-82
years of
age

Men, non-pregnant, nonlactating women aged 18
years or older with a
diagnosis of Type 1 or
Type 2 diabetes and
diabetic gastroparesis
who were willing to
discontinue current
gastroparesis treatment
for at least 7 days before
dosing until the end of the
6-week study. Baseline
requirement of a score
between 8-20 on
SAQ and IAQ scale with
at least 2/6 symptoms on
the SAQ and IAQ rated
moderate or higher (≥2)
for frequency and severity
was required.

Patients with
abnormal
chemistry or
hematology
parameters
(with the
exception of
plasma
glucose), and
an estimated
creatinine
clearance of
<40 mL/min
were
excluded.

7

Metoclopramide
20 mg Nasal
Spray
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OUTCOMES MEASURED
Throughout these studies, patients graded their symptoms on a scale based on change
whether they improved, worsened, or stayed the same after the use of metoclopramide. In one
study, a Clinical Patient Grading Assessment Scale (CPGAS) was used. 5 In another study,
patients kept track of their symptoms by recording the data in a Gastroparesis Cardinal Symptom
Index Diary.6 In the last study, investigators assessed patient’s symptoms and their severity
through an Investigator’s Assessment Questionnaire. after patients had filled out a Symptom
Assessment Questionnaire (SAQ).7
RESULTS
All three studies used an intervention of metoclopramide whether it was in a nasal or oral
form. Two studies used nasal metoclopramide as interventions comparing it to placebo or a
control. One study, a case analysis, used an intervention of metoclopramide but had no control or
comparison group. All studies used participants above the age of 18 including men and women
with gastroparesis symptoms. In all three studies, patients under the age of 18 were excluded.
Subjects with high glucose readings were also excluded to maintain proper glycemic levels, since
a side effect of metoclopramide includes hyperglycemia.5,6,7 Parkman’s 2015 double blind RCT
excluded patients whose gastroparesis symptoms were too mild, as metoclopramide was not
needed, or to severe, to maintain safety form adverse effects. 6 In this double blind RCT, two
subjects did not complete the experiment due to withdrawal of consent and another subject
having a history of chronic pancreatitis. 6 In Parkman’s 2014 open label RCT, 92.1% subjects
completed the study, and seven subjects withdrew from the study due to side effects. 7
Parkman’s 2014 RCT open label study evaluated the change in symptoms from baseline
with the intervention of nasal metoclopramide 20 mg and compared it to oral metoclopramide 10
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mg at six study sites across the United States. 7 The intervention of nasal metoclopramide 10 mg
was also used in this study, however, this paper will solely focus on the nasal metoclopramide 20
mg compared to the oral metoclopramide 10 mg. Eighty-nine diabetic participants were assessed
in this study for six weeks and were given metoclopramide four times a day. A symptom
assessment questionnaire (SAQ) was used where patients rated the symptom severity before,
during, and after the treatment. Symptoms included nausea, vomiting, anorexia, bloating, early
satiety, and meal tolerance. A score between 0 to 4 was given. Then, the investigator’s
assessment questionnaire (IAQ) was used by investigators to rate the severity for each patient as
well by interviewing each patient. The mean total symptom score (TSS) reduced about 13 points
for nearly all patients from baseline after 1 week of treatment. The data showed that 97.1% of the
participants who received nasal metoclopramide 20 mg and 88.9% who received oral
metoclopramide 10 mg responded to the treatment.7 The nasal 20 mg metoclopramide group had
a confidence interval of (-7.1,-0.5) with a p-value of 0.026 as shown in Table 2.7
Table 2: Comparison of Efficacy through Mean Change from Baseline to Outcome
Treatment
N
Baseline
Mean change
95% CI
p-value
Metoclopramide
Mean
from baseline
Nasal 20 mg7

35

21.3

-18.0

(-7.1, -0.5)

0.026

Oral 10 mg7

18

22.9

-14.3

N/A

N/A

The data from the study was calculated to get the number needed to treat (NNT) which was 13 as
shown in Table 3. 13 people need to be treated with metoclopramide in order to have one
successful outcome in reducing symptoms of gastroparesis.
Table 3: Statistical Analysis of Parkman’s Efficacy in Improving Symptoms
NNT
RBI
ABI
13
0.092
0.082
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Parkman’s 2015 RCT double blinded study used 14 mg nasal metoclopramide as its
intervention and compared it to a placebo. This study used participants between the age of 18 to
75 who also had a diagnosis of diabetes and a gastroparesis similar to Parkman’s 2014 RCT open
label study. These 225 participants were monitored in the United States at various
gastroenterology or mixed specialty practices that treated gastroparesis. 6 Four symptoms were
monitored throughout this study which included nausea, bloating, early satiety, and upper
abdominal pain.6 This study also used nasal metoclopramide 10 mg, however, this paper will
focus only on the placebo compared to the nasal 14 mg metoclopramide. Subjects recorded
symptom severity on the Gastroparesis Cardinal Symptom Index Daily Diary. 6 Compliance of
males completing daily diary recordings was 90% and 86% for females.6 They were required to
grade each symptom from 0 to 5. The study did not show a confidence interval however a pvalue of 0.3005 comparing the placebo to the 14mg metoclopramide was reported which is not
statistically significant.6 The change from baseline to end of the study showed a mean and
standard deviation of -1.2(0.94) compared to the placebo -1.0(0.89).6 This study also focused on
the changes in symptoms between males and females. Women with nasal metoclopramide had
more improvements with symptoms reported by the change from baseline to week 4 with a mean
and standard deviation of -1.3(0.98) as compared to males -0.9(0.78). Males seemed to have a
greater response to the placebo with a mean and standard deviation of -1.4(0.98).6 This data is
shown in Table 4.
Table 4: Mean Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD) Total Score
Change from Baseline to Week 46
Placebo (N=95)
MCP 14 mg Nasal (N=96)
Baseline, mean (SD)
2.8(0.57)
2.8(0.062)
Week 4, mean (SD)
1.8(1.00)
1.7(0.90)
Change from baseline to week 4
-1.0(0.89)
-1.2(0.94)
p-value
N/A
0.3005
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Women -Baseline, mean (SD)
Male -Baseline, mean (SD)
Women - Week 4, mean (SD)
Men - Week 4, mean (SD)
Women - Change from baseline to week 4
Men - Change from baseline to week 4

2.7 (0.54)
2.9(0.63)
1.9 (1.02)
1.4(0.84)
-0.8(0.79)
-1.4(0.98)

2.9(0.62)
2.5(0.56)
1.7(0.94)
1.7(0.79)
-1.3(0.98)
-0.9(0.78)

The last study, Parkman’s case analysis, focused on 100 participants who were regularly
taking metoclopramide for gastroparesis, 34 of these patients had a diagnosis of diabetes.5
Patients assessed their symptoms using the Clinical Patient Grading Assessment Scale from a
score of -3 to 3. The study stated that 53% of the participants had improvement with taking
metoclopramide with a p-value of 0.83.5 This study further investigated side effects and found
that 64% of the participants reported side effects to metoclopramide. 5 Side effects included
anxiety, akathisia, fatigue, tremors, depression, dystonia, seizures, and tardive dyskinesia. The
study reported that side effects were often more reported in the 77% of non-diabetic patients
rather than diabetic gastroparesis patients. 5
The other two studies also reported side effects of headaches, fatigue, nausea, vomiting,
dysgeusia, drowsiness, and restlessness. Parkman’s RCT open label study found an increase in
side effects in oral 10 mg metoclopramide compared to nasal 20 mg metoclopramide. There were
no reported deaths in any of the studies. The greatest side effects reported conclusively from all
three studies were those affecting the central nervous system. The complaints reported by
patients in each study listed by frequency are shown more thoroughly by various body systems in
Table 5.
Table 5: Adverse Effects reported by frequency of participants in each study
Adverse Effects
Nervous System (HA, Dizziness,
akathisia, tremors, tardive
dyskinesia, dystonia, confusion,
seizure, dysgeusia)
Psychiatric
(depression, anxiety)

Parkman’s RCT
Open Label7
1

Parkman’s RCT
Double Blind6
24

Parkman’s Case
Analysis5
31

0

0

15
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Gastrointestinal (diarrhea,
vomiting, nausea)
Metabolic (hyperglycemia,
hypoglycemia)
Respiratory (cough, epistaxis,
cough, rhinorrhea, throat
discomfort)
Infections (URI)

3

6

0

0

6

0

0

14

0

0

3

General (fatigue)

0

6

Skin (rash)

1

0

Miscellaneous

0

0

9

9

DISCUSSION
There were many limitations seen in these studies. All three studies used questionnaires
for patients to fill out as their main source of composing and collecting data. The scoring range
scale in each of the studies was different making it difficult to align the data together.
Metoclopramide, brand name Reglan, is a dopamine 2 receptor antagonist, a 5-HT4
agonist, and a weak HT3 receptor agonist, which the FDA has approved for the treatment for
gastroparesis for 12 weeks, longer if the benefits are greater than the risks.5 However,
Metoclopramide has a black box warning for tardive dyskinesia. 3 Parkman’s 2012 case analysis
also failed to report the duration of the study making it not a reliable source to administer
treatment in a patient. Furthermore, the open label case analysis reported adverse effects of
tardive dyskinesia and many other central nervous system adverse side effects. CNS side effects
cause hesitation in administering treatment in patients, especially those that involve movement
disorders like tardive dyskinesia.
Metoclopramide is the only approved treatment for gastroparesis by the FDA and is
easily accessible to most patients through health insurances. 3 It is also easily available
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throughout the United States with a prescription. Oral tablet form is more common than nasal
metoclopramide.4 Injection form is also available.
CONCLUSION
Other resources have shown that metoclopramide is the only approved treatment for
gastroparesis. However, these three studies did not show collective data to show that
metoclopramide is effective in treating symptoms in gastroparesis. These studies also showed
adverse effects of metoclopramide, some of which included seizures, tardive dyskinesia, and
other movement disorders which makes treating a patient with this drug highly questionable.
Further investigation showed that only 2 patients developed tardive dyskinesia from Parkman’s
2012 case analysis.5 The studies showed that metoclopramide is safe and moderately tolerable in
most patients, and less side effects when used in diabetic patients. No deaths occurred in the
trials either. This drug has FDA approval which allows for more use by physicians and less risks
when used in patients, however, the data conclusively in all studies do not support evidence to
prove the efficacy of metoclopramide. Parkman’s 2012 case analysis had no comparison group
and used any dose of metoclopramide and any duration of time metoclopramide was being used
by patients. Parkman’s 2015 study compared to a placebo while Parkman’s 2012 group
compared to another dose of metoclopramide. There was no common comparison group in any
of the studies and only Parkman’s 2014 study showed to be statistically significant. Further
studies should be conducted specifically in groups of people who have developed tardive
dyskinesia, seizures, akathisia, or other CNS adverse effects to see if the therapeutic benefit of
metoclopramide does in fact outweigh the risks, and trials that are longer in duration.
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